Indian Journal of Microbiology Микробиология

Nanoengineered Hydroxychloroquine-ZnO for Broad-Spectrum Antibacterial Therapy with Reduced Cytotoxicity

Rani, Swati, Devi, Jai, Kumar, Balvinder, Prasad, Minakshi, Manuja, Anju
Springer Nature · 2026-09-23 · DOI 10.1007/s12088-026-01577-1

Аннотация

The development of multifunctional nanomaterials integrated with small-molecule therapeutics offers a promising strategy to enhance antimicrobial efficacy while minimizing host toxicity. In this study, we report the rational design of a hydroxychloroquine-zinc oxide nanocomplex (HCQ-ZnONPs) that enhanced the hydroxychloroquine's intracellular interference with the broad-spectrum antimicrobial properties of zinc oxide nanoparticles. The nanocomplex was synthesized and characterized using different techniques as FT-IR and ^1H NMR to see the interactions of the components used and to determine the binding sites respectively. It indicated successful formation of the HCQ-ZnONPs. The average particle size of 28.42 nm of the complex was determined using XRD while SEM revealed a morphology of the flattened leaf-like for HCQ-ZnONPs and rod-shaped for ZnONPs. EDAX confirmed the presence of C, O, N, and Zn. The HCQ-ZnONPs complex exhibited the highest activity against S. equi (88.85%) and S. aureus (88.19%) at 10 mg/mL, significantly surpassing the individual activities of HCQ and ZnONPs ( p < 0.0001 ), confirming enhanced antibacterial action against Gram-positive bacteria. Whereas, the HCQ-ZnONPs complex showed comparatively moderate inhibition (60.76%) against E. coli , a Gram-negative strain but still statistically higher than the individual components (HCQ and ZnONPs) ( p < 0.05), indicating that conjugation improves antibacterial efficacy even against Gram-negative organisms. Molecular docking studies further predicted a favorable binding affinity (− 6.9 kcal/mol) of HCQ-ZnONPs for fibronectin-binding proteins which are present in S. equi and S. aureus. Collectively, these findings highlight HCQ-ZnONPs as a promising antimicrobial platform that combines enhanced antibacterial potency with improved biocompatibility. It provides a foundation for the further studies for development of next-generation hybrid therapeutics to combat bacterial resistance.

Читать у издателя →